HR and breast cancer: The other two [74,75] involved one expert from the UAE among other international experts from countries like Argentina, Brazil, Colombia, Egypt, Mexico, Moscow, and South Korea, Singapore, and Taiwan and were therefore not specific to the regional GCC context, and while one focused on treatment selection in HR+HER2− metastatic BC (mBC) [75], the second was more focused on the BRCA testing and management of HR+ HER2-mBC in the era of poly (ADP-ribose) polymerase inhibitors (PARPi) [74].